Summary N-(2-Hydroxypropyl)methacrylamide (HPMA) copolymers containing doxorubicin (DOX) 
Summary N-(2-Hydroxypropyl)methacrylamide (HPMA) copolymers containing doxorubicin (DOX) and galactosamine can be targeted to the hepatocyte galactose receptor for organ-specific chemotherapy of primary and metastatic liver cancer. Here we report the dose-dependent pharmacokinetics of this macromolecular conjugate. Following intravenous administration to mice most efficient liver targeting was seen at low dose (0.05 mg DOX kg-'), with receptor saturation observed using higher bolus doses. Repeated low dose bolus injections did not cause down-regulation of the galactose receptor and targeted drug delivery rates of > 2 ;g DOX g-I liver h-' were achieved. DOX is released from such conjugates intracellularly via action of lysosomal proteinases. It was shown that isolated rat liver lysosomal enzymes (Tritosomes) can release unmodified DOX from the peptidyl side chain Gly-Phe-Leu-Gly at a rate > 3 fig DOX g-liver h-' i.e. the hydrolytic capacity is greater than the observed rate of drug delivery to the liver lysosomes in vivo. Although most conjugate would be captured by normal hepatocytes following intravenous administration, it was shown that the human hepatoma cell line HepG2 retains the galactose receptor, accumulating and processing the conjugate efficiently. Potential dose limiting toxicities of such drug conjugates could include cardio-or hepatotoxicity. Administration of conjugate reduced the 15 min heart level of DOX approximately I 00-fold compared with that observed for an equivalent dose of free drug. Preliminary experiments showed that plasma levels of alkaline phosphatase, alanine transaminase and asparate transaminase did not change following administration of HPMA copolymer-daunorubicin (DNR) (10 mg DNR kg-') indicating no significant heptatoxicity.
On a worldwide basis, liver cancer is one of the major causes of cancer mortalities. In Western Europe 20-25% of all cancer deaths results from metastatic liver cancer, while in parts of Africa and Asia primary hepatocellular carcinoma alone accounts for nearly 40% (Cady, 1983; Nerenstone et al., 1988) . Surgical resection affords the possibility of cure for localised tumours, but it is generally not suitable for patients who present with diffuse disease. Similarly, chemotherapy is effective in only a small percentage of cases, and the prognoses of patients with either primary or secondary liver cancer are generally very poor (the 5-year survival rates for primary hepatoma and liver-metastatic colorectal carcinoma are only 3% and 2%, respectively).
Targeted drug delivery may permit improved chemotherapy of liver tumours at two different levels. At the first level, a number of systems have been developed for liverspecific therapy. The approach which has seen the most clinical development to data involves infusion of drug-laden microspheres into the hepatic artery, causing them to become entrapped within the microvasculature with subsequent elevation of drug levels in the vicinity of tumour tissue (Kerr, 1989) . However, the application of this technique is restricted by its invasive nature, and intravenous delivery systems have been sought. One such approach has used drug-laden nanoparticles that rapidly associate with Kupffer cells, from where drug can diffuse into nearby tissues and produce high local concentrations (Chiannilkulchai et al., 1989) . Alternatively, liver-specific targeting can be achieved intravenously using vehicles designed to interact with liver-associated receptors, such as the hepatocyte galactose receptor (Vera et al., 1985; Ceulemans et al., 1987; Dragsten et al., 1987) ; the fenestrated endothelial membrane of the liver allowing macromolecular access to the hepatocyte surface, combined with the abundant numbers of galactose receptors, makes them a suitable target (Fallon & Schwartz, 1989) .
At the second level therapy can be directed to the tumour, for example by administration of antibodies interacting with tumour-associated ligands, such as CEA and ferritin (Order et al., 1980) . Indeed, the hepatocyte galactose receptor itself is retained by some human primary hepatomas (Schneider et al., 1984) and may represent a useful target for the treatment of this disease.
Following the observation that soluble N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers containing anthracyclines display anti-tumour activity in vivo Cassidy et al., 1989) we have explored the potential of this polymer-based system for targeted delivery of doxorubicin (DOX) to the hepatocyte galactose receptor. HPMA Copolymers have previously been synthesised containing galactose (Duncan et al., 1983a; Duncan et al., 1986; O'Hare et al., 1989) and are known to associate with human hepatoma cell lines in vitro (O'Hare et al., 1989) and also show livertargeting in vivo (Chytry et al., 1987) . The galactose-targeted polymer is associated with hepatocytes rather than nonparenchymal cells, and it is transferred into lysosomes within 1 h of intravenous administration (Duncan et al., 1986) . Careful choice of the drug-polymer linkage can ensure that the drug is released only following internalisation and subsequent cleavage by lysosomal enzymes; the conjugate is completely stable and inactive in the bloodstream (Duncan et al., 1983b; Rejmanova et al., 1985) .
To optimise drug targeting to the liver it is necessary to understand the dose dependency of the galactose receptor, and to identifiy the rate-limiting step in drug delivery. In particular it is important to establish whether administration of the targeted drug conjugate causes the receptor to become down-regulated, and also to quantify the capacity of intracellular lysosomal hydrolysis since this could limit the rate of drug delivery. In addition the possibility of anthracycline toxicity (particularly cardiotoxicity and hepatotoxicity) should be assessed when the drug is presented in conjugate form.
To address these questions HPMA copolymers were synthesised containing DOX or daunorubicin (DNR) and galactose. The kinetics of liver-targeting were assessed in vivo at various doses using radioiodinated copolymers, and libera-tion of free drug from the conjugate was studied by HPLC in vitro using isolated rat liver lysosomal enzymes, and also in cultured human hepatoma cells (HepG2). The (Rihova et al., 1989) . The weight average molecular weight and polydispersity of the polymeric precursors (before conjugation to DOX or sugar) were determined using Sepharose 4B/6B gel permeation chromatography (Strohalm & Kopecek, 1978) . To facilitate radioiodination, certain copolymers were prepared which contained methacryloyltyrosinamide as comonomer (1.0 mol%) units (Duncan et al., 1981) . Chemical characteristics of the polymer conjugates are shown in Table I and the structure of Conjugate 3 is represented in Figure 1 .
Measurement ofpharmacokinetics in DBA2 mice using radioactivity Tyrosinamide-containing copolymers were radiolabelled with 1251I iodide using an iodogen technique (Seymour et al., 1990) , to give a specific activity of approximately 50 giCi mg l conjugate. Materials were always purified by Sephadex G-25 column chromatography immediately prior to use in order to remove all free 1251 iodide.
To quantitate blood clearance and liver accumulation it was important first to estimate precisely the DBA2 mouse circulation volume available to DOX-HPMA copolymer conjugates. 251I-Labelled Conjugate 1 (not containing galactosamine) was considered the most appropriate probe for this purpose due to its relatively slow blood clearance (Seymour et al., 1990) . It was administered intravenously (via the tail vein, at a dose of 0.05 mg DOX kg-') and a blood sample (20 ptl) taken 1 min later. Assay of the radioactivity content of the sample, together with knowledge of the amount of radioactivity administered, permitted the dispersion volume to be calculated. Using this technique the blood volume (for HPMA-DOX) was found to be 8.64 ± 0.25 ml blood 100 g-' body weight. In the same experiment the liver was isolated, rinsed in cold phosphate buffered saline, weighed, homogenised in water to a known volume and assayed for contained radioactivity. Assuming that the radioactivity associated with liver at 1 min was due entirely to polymer-conjugate present in ocluded blood, it is possible (using the amount of radioactivity detected in the blood sample) to calculate the volume of blood occluded in the liver and this was found to be 0.14 ± 0.01 ml g-' liver. The above values were used throughout to calculate the blood volume and blood occluded in the liver.
For subsequent studies substrates were injected via the tail vein into lightly-anaesthetised DBA2 mice at known total doses of DOX, and the 251I-labelled conjugates (1 and 3) were always administered at a dose of DOX equal to 0.05 mg kg-'. To study the dose dependancy of clearance and liver accumulation of galactosamine-containing polymers the nonradiolabelled Conjugate 2 was coadministered with the radiolabelled Conjugate 3 to give a total DOX dose of 0.05-15.0 mg kg-'. Mice were maintained under anaesthetic throughout, and blood samples (20 slI) were taken from the tail over a 60 min period and assayed for radioactivity. The initial blood level was calculated from knowledge of the total radioactive dose administered and the volume of dispersion calculated above. After 60 min animals were killed by cervical dislocation and the liver removed, rinsed in phosphate-buffered saline, and homogenised in a known total volume of water prior to radioactivity assay. The radioactivity present in the carcass and excreta were measured following its dissolution in sodium hydroxide (10.0 M, 850C, 60 min).
In certain experiments multiple doses of polymer-DOX were administered. The first series of experiments involved intravenous injection of Conjugate 2 (5.0 mg DOX g-'), followed (24 h later) by administration of radiolabelled Conjugate 3 (0.05 mg DOX kg-'). Blood samples were taken over a 60 min period following the latter injection. A second series of experiments was carried out in which hourly doses of polymer-DOX (0.5 mg DOX kg-') were given for periods Gly-Phe-Leu-Gly-Gal Gly-Phe-Leu-Gly-Gal 4.0 -aValues of M. and MW/Mn (polydispersity) were calculated from gel permeation chromatography data (Strohalm & Kopecek, 1978 (1984) and quantitation of polymer-bound DOX was achieved by releasing the DOX from the conjugate using acid-hydrolysis (Seymour et al., 1990 ).
Degraduation of HPMA copolymer-DOX by lysosomal enzymes in vitro Male Wistar rats were injected intraperitoneally with the detergent Triton WR1339 and 4 days later their liver lysosomes (Tritosomes) were purified using methods previously described (Trouet, 1974 The effect of multiple bolus injections was examined using two schedules. In the first series of experiments it was shown (Figure 3a) that the bloodclearance profile of a small dose (0.05 mg DOX kg-') of radiolabelled Conjugate 3 given 24 h following a large dose (5.0 mg DOX kg-') of Conjugate 2 was indistinguishable from the clearance observed in previously untreated animals, indicating that the receptor is not permanently saturated or down regulated by the higher dose. In subsequent experiments bloodclearance of repeated doses (administered hourly) of conjugate (0.5 mg DOX kg-') was followed. Up to four consecutive hourly doses were given and Conjugate 3 was cleared from the bloodstream at the same rate throughout (Figure 3b) .
The liver accumulation of radiolabelled Conjugate 2 after 1 h was greatest (up to 45% of the dose administered) at the lowest doses examined (0.5 mg DOX kg-'). Because a large proportion (over 25%) of the administered conjugate is lost via urinary excretion during the 60 min experiment, this amount accounts for over 70% of the radioactivity remaining in the body at the time of sampling. Increasing the dose of conjugate resulted in decreased efficiency of liver-targeting; at doses of Conjugate 2 containing 5 mg DOX kg-' and above the radioactivity recovery in the liver was only 2-4% of that administered (Figure 4a) . Expression of DOX accumulation by the liver in absolute amounts (ng DOX g-liver) as a function of dose shows a biphasic profile with an initial steep rise (up to 0.5 mg DOX kg-'), and then a slower increase directly proportional to the dose administered (Figure 4b ).
Lysosomal degradation of conjugates in vitro When Conjugate 4 (at various concentrations) was incubated with Tritosomes in vitro, there was progressive release (linear with time up to 5 h) of anthracycline, appearing as a single peak on HPLC analysis (co-eluting with free DOX). Increasing substrate concentration caused a fall in the percentage of polymer-bound DOX released over the 5 h (again linear with time over this period), although the absolute amount liberated was independent of concentration (Table II) . Clearly under these conditions the concentration of enzymes, and not substrate, was rate-limiting; the amount of DOX released over 5 h increased approximately linearly with the concentration of added enzyme. Measurement of heart levels of DOX A peak heart level for free DOX of about 12 ytg DOX g-' tissue was detected 15 min following administration of free DOX (5 mg kg-'); this was decreased 100-fold when the drug was given at equal dose in conjugate form (Figure 7) . The amount of free DOX detected in the heart following administration of galactose-targeted conjugate was the same as reported previously (Seymour et al., 1990) for non-targeted formulations; the presence of galactose has no apparent effect on free drug levels in the heart.
Assessment of release of liver enzymes
Mice administered Conjugate 6 (10mg DNRkg-') showed no differences from controls in either body weight or in the plasma levels of alanine transaminase, aspartate transaminase or alkaline phosphatase over the duration of the experiment. On autopsy their livers appeared to be normal (results not shown). Figure 7 DOX concentration in the heart following intravenous administration of free and polymer-bound DOX. Conjugate 2 (5 mg DOX kg-') was administered intravenously and the free DOX (0) measured using HPLC. Results obtained were compared to those detected following administration of free DOX (5 mg kg-') (0). distribution governed mainly by molecular weight-dependent extravasation and glomerular filtration (Seymour et al., 1987) . Their slow accumulation by cells is via fluid-phase pinocytosis (Duncan et al., 1981) , an uptake mechanism which is not saturable and where the amount of material captured is directly proportional to its concentration in the extracellular fluid (Williams et al., 1975a) . In contrast, copolymers containing targeting residues (e.g. Conjugate 2) can also enter target cells by receptor-mediated pinocytosis. This process involves the substrate binding to specific receptors on the plasma membrane and constitutes an efficient method of uptake at low substrate concentrations, although it typically shows receptor-saturation at high concentrations (Williams et al., 1975b) .
In this study we have examined the kinetics of galactosetargeted polymer-doxorubicin conjugates which are principally suitable for organ-specific therapy of primary and secondary liver cancer. We found that bloodclearance of intravenously injected galactose-targeted conjugates was very rapid at low doses (Figure 2) , and the material was captured efficiently by the liver (Figure 4a ). With increasing dose, the rate of bloodclearance and liver accumulation gradually fell (in percentage terms) until, at a dose of 15 mg kg', behaviour was indistinguishable from that of a galactose-free control polymer.
When liver-deposition is expressed in absolute quantities of DOX it is clear that at low doses there was enhanced accumulation due to galactose-mediated pinocytosis, while at higher doses the amount of material accumulated was proportional to the dose, suggesting uptake by a non-specific process such as fluid-phase pinocytosis. Kooistra et al. (1979) showed the hepatic rate of fluid-phase accumulation of 1251_ labelled poly(vinylpyrrolidone) to be approximately 1.6 ml plasma/day in the rat. Simple conversion on a weight basis suggests the corresponding figure for mouse liver would be approximately 0.01 ml plasma/mouse/h (or 1% plasma volume/h-'). Data shown in Figure 4b indicate a rate of non-specific clearance of Conjugate 2 to be equivalent to 3-4% plasma volume/h-'; therefore other factors (such as non-specific adsorptive pinocytosis) may also contribute to the liver capture of galactose-targeted HPMA copolymer-DOX conjugates. This would not be surprising in view of the affinity of DOX for interaction with membranes (Brown & Imam, 1984) .
The efficiency of liver-targeting of Conjugate 2 observed here can be compared with extensive literature describing the physiological functioning of the galactose receptor. Estimates of average rate of uptake of galactose-bearing macromolecules by isolated rat hepatocytes are about 4 x 106 molecules internalised/cell/h (Warren & Doyle, 1981; Schwartz et al., 1982) . Given that there are about 1.6 x 108 cells g-' moist liver (Pardridge et al., 1983) (Baenziger & Maynard, 1980) , levels are known to show considerable variation between mammals (including mice, guinea pigs, rats and rabbits (Chang & Chang, 1988) ); there is, as yet, no definitive study of the saturability of the receptor in man.
In addition to organ-specific drug delivery, targeting to the galactose receptor may also permit tumour-selective therapy since some human primary hepatomas are known to retain the galactose receptor (Schneider et al., 1984 (Figure 6 ).
The polymer conjugates described here can be thought of as macromolecular prodrugs as they require activation by lysosomal enzymes in vivo to release free DOX. It is therefore important to establish whether the liver lysosomal enymes have adequate proteolytic capacity to hydrolyse the quantities of drug conjugate that will be presented to them during therapy. Otherwise lysosomal enzyme activity rather than galactose-mediated targeting would constitute the rate limiting step for drug delivery. Use of isolated Tritosomes permits direct study of kinetic parameters relating to lysosomal degradation (Duncan et al., 1983c Figure 5 ). These observations correlate well with the known antitumour activity of the form type of conjugates and the lack of activity of the latter (Seymour et al., 1990 ) that conjugation of DOX to HPMA copolymers can decrease the 15 min heart level of free drug by about 100-fold, and here we have shown that the same is true for HPMA-DOX conjugates containing galactose (Figure 7) . In a sensitive test for anthracyclinemediated cardiotoxicity in rats, measuring cardiac output, the toxicity of the polymer conjugate has been shown to be substantially decreased compared with equivalent doses of the free drug (Yeung et al., 1989 seemed to impair the galactose recognition system irreversibly.
The efficiency of galactose-targeting of drug conjugates may be improved by manipulation of their molecular weight.
It is known that the weight average molecular weight threshold limiting glomerular passage of HPMA copolymers is about 45 kD (Seymour et al., 1987) , and the use of conjugates of molecular weight higher than this would prevent rapid renal elimination. The galactose receptors of the liver are the only quantitatively-significant galactose recognition systems in the body (Schlesinger et al., 1980) ; hence administration of large doses of a high molecular weight drug conjugate, although initially saturating the liver receptors, should allow the excess to remain in the circulation thus being available for capture by the recycling hepatic galactose receptors. Such conjugates would permit single high dose bolus injections leading to selective liver-deposition of therapeutically useful quantities of drug, and they are currently undergoing extensive pharmacokinetic evaluation and testing against animal models of hepatic malignancies.
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